Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
244 institutional managers report a position in Summit Therapeutics Inc. worth $2.1B between them, filed on form 13F for the quarter ending 2026-06-30. 23 of them hold 80% of it, the largest being Baker Bros. Advisors LP at 22.99%.
219 more managers in the register
23 managers hold 80% of the $2.1B institutional base. The other 221 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via Baker Bros. Advisors LP, Point72 Asset Management, L.P., Norges Bank +3 more · 22.99% of SMMT, 25.37% of ACAD
via Baker Bros. Advisors LP, Diadema Partners LP, Schroder Investment Management Group +3 more · 22.99% of SMMT, 28.87% of BCYC
via Baker Bros. Advisors LP, Adage Capital Partners GP, L.L.C., Diadema Partners LP +2 more · 22.99% of SMMT, 32.23% of KOD
via Baker Bros. Advisors LP, Standard Life Aberdeen plc · 22.99% of SMMT, 32.31% of SERA
via Baker Bros. Advisors LP, Marshall Wace LLP, Candriam Luxembourg S.C.A. · 22.99% of SMMT, 25.03% of ONC
via Baker Bros. Advisors LP, Marshall Wace LLP · 22.99% of SMMT, 27.03% of ABCL
Managers holding a meaningful stake in SMMT also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
Summit Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 17.41 · gapped above the open, then crossed back over prior close. High/low 18.52 at 4:00 am ET, 17.17 at 1:00 pm ET.
SMMT (Summit Therapeutics Inc.) has 6 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JPM +0.17%, in financials.